Proactive Investors - Run By Investors For Investors

Sareum’s flagship Chk1 inhibitor shows serious lung cancer potential in mouse models

After 50 days, eight out of ten mice achieved a complete response, which means there was no detectable sign of cancer anymore
Although promising, studies are still only at an early stage

Sareum Holdings Plc (LON:SAR) shot higher on Tuesday after data presented at a massive industry conference showed that its flagship Checkpoint 1 inhibitor was able to remove any evidence of lung cancer in mice.

When combined with low-dose gemcitabine – commonly-prescribed in chemotherapy – and an anti-PD-L1 immunotherapy, SRA737 demonstrated “dramatic anti-tumour activity”, Sareum said.

WATCH: Sareum boss looks ahead to critical Phase II data from SRA737

All ten of the mice with small cell lung cancer (SCLC) showed tumour regression at the end of the 21-day treatment period. Eight of the mice showed sustained complete response after a further 39 days without receiving any more treatment.

A complete response doesn’t mean cured, but it is the best result that can be reported and means there is no evidence of the disease.

The data, which was presented at the American Association of Cancer Research in Atlanta, suggests this combination of SRA737, LDG and an anti-PD-L1 immunotherapy “may represent the optimal implementation of these agents,” said Sareum.

‘Very exciting’

“The model data presented are very exciting with all examples treated with SRA737, LDG and anti-PD-L1 showing tumour regression and 80% having a complete response, with no detectable cancer,” said Sareum chief executive Tim Mitchell.

“This provides a clear early demonstration of the potential of SRA737+LDG to enhance anti-PD-L1 immunotherapy in small cell lung cancer, a cancer type where such immunotherapies have shown limited benefit.”

He added: “We will follow the progress of studies using this novel combination approach with great interest.”

Sareum shares jumped 6.4% to 0.81p on Tuesday.

View full SAR profile View Profile

Sareum Holdings PLC Timeline

Big Picture
February 22 2019

Related Articles

Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year
Callitas CEO James Thompson
July 20 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
May 02 2019
Avacta is using Affimers to develop its own cancer therapy, but it also licenses the technology to other companies, including major pharma group ModernaTX and LG Chem Life Sciences

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use